RxDoctor Payments Data

Vincent Varghese, DO

Cardiovascular Disease · Marlton, NJNPI 1316145808

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (50.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 16.0%.

$18,346in general payments, 2019–2025

Across 165 payments — averaging $111.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Abbott$3K
  • Cagent Vascular Inc$2K
  • Siemens Medical Solutions USA, Inc.$2K
  • Terumo Medical Corporation$2K
  • Boston Scientific$2K
  • plus $6K from 18 others
$28,937in research payments, 2019–2025

Across 11 payments — averaging $2630.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abbott$15K
  • Bard Peripheral Vascular, Inc.$6K
  • Shockwave Medical, Inc$4K
  • Medtronic$3K

What the payments were for

  • Consulting fees$4,62525%
  • Speaking & faculty fees$6003%
  • Travel & lodging$2,84616%
  • Food & beverage$9,31751%
  • Other$9585%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,346 in reported general payments places this provider in the 85th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey →

Medicare billing

Part B allowed, 2024
$80,341
Medicare patients
150
Services billed
437

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Rosuvastatin Calcium53$1,074
Metoprolol Succinate35$499
ClopidogrelClopidogrel Bisulfate35$492
Carvedilol46$393
Valsartan11$388
Amlodipine Besylate68$297
Nitroglycerin14$280
Atorvastatin Calcium24$217
Losartan Potassium22$160
Metoprolol Tartrate16$148
Hydralazine Hcl11$147
Furosemide27$130
Pantoprazole Sodium11$101
Lisinopril14$80

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Marlton

See the full list for New Jersey →

Where these figures come from

Is this you, or does something look wrong? →